First, GLP-1RAs have been shown to inhibit the expression and release of proinflammatory cytokines, such as IL-6 and TNF-, thereby inhibiting the overall inflammatory response
A vial that was allowed to warm repeatedly, or that is nearing the end of its working window, may deliver a weaker last dose than its first which can masquerade as a plateau
2 Pathogenesis of DCM DCM is usually characterized as a contractile dysfunction with later onset of HF without association to dyslipidemia, hypertension or coronary artery disease, but instead caused by metabolic and humoral disruption in connection with hyperglycemia, hyperinsulinemia and insulin resistance ( The two main factors that drive DCM are long-term hyperglycemia and insulin resistance
Research supports the idea that slow titration allows your body to adjust to the drug's effects, reducing the severity of side effects, including nausea
[7] [8] Current recommendations suggest most patients can continue therapy with appropriate risk stratification rather than routine holds
What is the difference between a single dose and a double dose
